Feb 8, 2017
PTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J., Feb. 8, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the third annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne muscular dystrophy (DMD). STRIVE provides funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates.

"We are proud to continue the STRIVE program for DMD. The patients and organizations have been at the heart of everything we do at PTC and it is particularly rewarding to support programs to further develop new programs to support the Duchenne community around the world," said Mary Frances Harmon, Global Head of Patient Advocacy at PTC. "We have been inspired by the success of the projects from the past two years and its impact on the lives of families and we look forward to this years' proposals."

The program is aimed at improving the diagnosis and treatment of DMD patients, increasing the visibility of this devastating rare disorder and educating the general public and healthcare professionals, as well as identifying and fostering the next generation of DMD patient advocates. The deadline for submission of proposals is May 31, 2017, and awards will be announced on World Duchenne Awareness Day, on Sept. 7.

For more information and to apply, please visit the STRIVE Awards Program's website at: www.ptcbio.com/en/strive.

About PTC Therapeutics
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA, or mRNA, molecule is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com

For More Information:

Emily Hill
+ 1 (908) 912-9327

Jane Baj
+1 (908) 912-9167

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements, other than those of historical fact contained in this release are forward-looking statements, including statements regarding the future expectations, plans and prospects for PTC. Other forward-looking statements may be identified by the words "plan," "guidance," "anticipate," "believe," "estimate," "expect," "intend," "may," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this release except as required by law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-third-annual-strive-grant-award-program-for-duchenne-muscular-dystrophy-300403755.html

SOURCE PTC Therapeutics, Inc.

News Provided by Acquire Media